COMMUNIQUÉS West-GlobeNewswire

CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference

31/01/2025 - 14:00

— Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from participants who have received capsules from a more recently manufactured batch [...]

Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting

31/01/2025 - 13:35

NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel [...]

Quipt Home Medical Responds to Kanen Wealth Management

31/01/2025 - 13:30

Reaffirms commitment to enhancing shareholder value and strong corporate governance CINCINNATI, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “ Company ”) (NASDAQ: QIPT) (TSX: QIPT), a U.S. based home [...]

23andMe Launches New Genetic Report on Osteoporosis

31/01/2025 - 13:30

Provides 23andMe+ Premium members with insight into their likelihood of developing osteoporosis based on thousands of genetic variants SUNNYVALE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME [...]

SAB BIO to Participate in Upcoming Investor Conferences

31/01/2025 - 13:00

MIAMI, Jan. 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS ), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing SAB-142, a human anti- [...]

Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader

31/01/2025 - 13:00

NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host a virtual [...]

OKYO Pharma Announces Chairman and CEO Acquire Shares

31/01/2025 - 13:00

LONDON and NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), [...]

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

31/01/2025 - 12:30

TOKYO and CAMBRIDGE, Mass., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: [...]

Bavarian Nordic Receives Positive CHMP Opinion for Chikungunya Vaccine for Persons Aged 12 and Older

31/01/2025 - 11:50

First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old. The virus-like particle (VLP) single-dose chikungunya vaccine is expected to launch in key European markets in the first half of [...]

Director/PDMR Shareholding

31/01/2025 - 08:00

DXS INTERNATIONAL PLC (AQSE: DXSP) Notification of Director / PDMR Dealing DXS INTERNATIONAL PLC The Board of DXS International plc (the “Company” or “DXSP), the AQSE Growth Market quoted clinical decision support [...]

Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant

31/01/2025 - 07:00

Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant Approval based on positive results from the IMROZ phase 3 study that demonstrated [...]

Communiqué de presse : Sarclisa est le premier anti-CD38 approuvé en Chine pour le traitement du myélome multiple nouvellement diagnostiqué des patients non éligibles à une greffe

31/01/2025 - 07:00

Sarclisa est le premier anti-CD38 approuvé en Chine pour le traitement du myélome multiple nouvellement diagnostiqué des patients non éligibles à une greffe Approbation motivée par les résultats positifs de l’étude de [...]

Ultimovacs ASA Reports Fourth Quarter 2024 Financial Results and Provides General Business Update

31/01/2025 - 07:00

Oslo, January 31, 2025: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces its fourth quarter 2024 results today. Conference call [...]

Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform

30/01/2025 - 22:57

MELBOURNE, Australia and INDIANAPOLIS, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has completed the acquisition from antibody [...]

Diag-Nose.io, Graduate of CDL-Seattle, Closes Oversubscribed $2M Seed Round to Transform Respiratory Care with AI-Driven Precision Medicine

30/01/2025 - 22:38

Diag-Nose.io, a CDL-Seattle graduate, harnesses AI with RhinoMAP™ to redefine respiratory care, securing $2M in oversubscribed funding SEATTLE, Jan. 30, 2025 (GLOBE NEWSWIRE) -- A groundbreaking precision medicine [...]

Diag-Nose.io Expands to Bethlehem, PA, Following Oversubscribed $2M Seed Round Funding to Revolutionize Respiratory Diagnostics

30/01/2025 - 22:37

Diag-Nose.io sets new standards in respiratory care with AI and proteomics after a $2M seed funding success, now expanding to Bethlehem, PA BETHLEHEM, Pa., Jan. 30, 2025 (GLOBE NEWSWIRE) -- A groundbreaking precision [...]

Diag-Nose.io Opens Houston Office following oversubscribed $2M Seed Round to Measure Respiratory Treatment Success Using Proteomics & AI

30/01/2025 - 22:37

Diag-Nose.io launches Houston office to advance precise respiratory care using AI and proteomics after a successful $2M seed round HOUSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Diag-Nose.io, a cutting-edge biotech company [...]

Diag-Nose.io, Graduate of Stanford EENT Innovation, Closes Oversubscribed $2M Seed Round to Transform Respiratory Care with AI-Driven Precision Medicine

30/01/2025 - 22:37

Diag-Nose.io, a Stanford EENT Innovation graduate, secures $2M in oversubscribed seed funding to revolutionize respiratory care with precise, AI-driven diagnostics and treatment MENLO PARK, Calif., Jan. 30, 2025 (GLOBE [...]

Globus Medical Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call

30/01/2025 - 22:35

AUDUBON, Pa., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Globus Medical , Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full-year ended December 31 [...]